At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Dapagliflozin (drug)
- How long the study runs
- Study runs about 48 months (dates as stated)
- About the drug or intervention
- Dapagliflozin — drug: On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 40 Years and over
- Who
- All
- Number of participants
- 44
- Started
- 2023-12-14
- Last checked
- 2026-03
Plain English Summary
What is this study?
- • Testing a new treatment for chronic kidney diseases
- • Clinical study - 44 participants
- • This is a feasibility study to assess new, more practical ways of measuring renal reserve
Who can take part?
- • Ages 40 Years and over
- • Diagnosed with chronic kidney diseases
Where?
- • London - King's College Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This is a feasibility study to assess new, more practical ways of measuring renal reserve.
More detail
Quantification of glomerular filtration rate (GFR) over time is the standard assessment of kidney function. In clinical practice, the endogenous marker, 'serum creatinine' concentration, is used as a static assessment of kidney function to estimate GFR. However, serum creatinine fails to increase until at least 50% of kidney tissue is lost,\[2\] thus is an inadequate indicator of early CKD. GFR like many other physiological processes is not static and augments temporarily to stimuli such as exercise and protein intake, by up to 25% from baseline in healthy individuals.\[3\] Similar to cardiac function stress tests which predict adverse outcomes, inability to respond to renal stressors or 'reduced renal reserve' has been demonstrated to occur prior to development of CKD (e.g. in patients with diabetes and previous acute kidney injury (AKI)) and is associated with vulnerability to future AKI, despite the presence of apparently normal kidney function measured by serum creatinine concentration.\[4\] Renal reserve is lost with progressive CKD,\[4\] and has also been demonstrated to relate to severity of histological lesions.\[5\] Current measurements of renal reserve (stimulated increase in GFR due to augmented renal blood flow above basal fasting values) involve administration of a compound that is freely filtered by the glomerulus, unaffected by tubular function and is physiologically inert, with assessment before and after an oral protein load or amino acid infusion which induces arterial vasodilation, increasing renal blood flow and GFR The study proposes a comparison of two novel methods of 'dynamic renal function testing' with renal reserve testing.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 40 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Inclusion:
- ✓Patients with sickle cell nephropathy, diagnosed clinically or histologically. Sickle Cell patients will be...
- ✓Previous living kidney donation
- ✓Age ≥ 4No safety concern or known allergy to any trial medications.
- ✓Willing and able to provide written agreement to take part
See the full criteria
Where Is This Study? (1 UK site)
King's College Hospital
London, United Kingdom
How to Get in Touch
Kate Bramham, Doctor
Sponsor contactCONTACT
